Mission-critical activities of HHS will continue during the Democrat-led government shutdown. Please use this site as a resource as the Trump Administration works to reopen the government for the American people.

Ribavirin and Interferon Therapy in Patients Infected with the Middle East Respiratory Syndrome Coronavirus An Observational Study

Al-Tawfiq, J.A., Momattin, H., Dib, J., and Memish, Z.A. (2014). Ribavirin and Interferon Therapy in Patients Infected with the Middle East Respiratory Syndrome Coronavirus: An Observational Study. International Journal of Infectious Diseases. 20:42-6.
The authors reviewed the therapeutic schedule and outcomes for five MERS patients who received ribavirin and interferon combination therapy an average of 19 days post-admission. None of the patients responded to therapy and all died, suggesting that this therapy is ineffective in patients with co-morbidities who start treatment late in the course of their illness.
Favorite:
You must Login to add a comment
  • This item doesn't have any comments

Enter your email address to receive important announcements and updates through the ASPR TRACIE Listserv.